Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Cassava Sciences (SAVA) Upgraded to Strong Buy by sfbancBy: sfbanc The drug in development purportedly works by retiring the proper conformation of filamin A, a molecule involved in the cascade of Alzheimer's disease. Open-label results are showing effectiveness in 84% of subjects treated. These promising results, along with recent insider buying, has led the sfbanc community to upgrade the stock. Additional results from the open label trial are expected by the end of this year. Call volume shows optimism for the results of the Cognitive Maintenance Study (CMS) in late 2023. This trial will include 100 subjects randomized to switch from active drug to placebo. Simufilam is currently in two randomized placebo-controlled Phase 3 trials. sfbanc is a financial community that provides analysis and discussion of available public information in the finance sector. https://sfbanc.com End
|
|